LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report)'s stock price dropped 6.3% on Friday . The company traded as low as $31.78 and last traded at $31.78. Approximately 8,168 shares traded hands during trading, a decline of 94% from the average daily volume of 136,605 shares. The stock had previously closed at $33.93.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on LENZ. William Blair raised shares of LENZ Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. Raymond James assumed coverage on shares of LENZ Therapeutics in a report on Friday, September 27th. They set an "outperform" rating and a $37.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price target on shares of LENZ Therapeutics in a report on Thursday, November 7th. Finally, Piper Sandler reiterated an "overweight" rating and set a $36.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, August 15th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $35.40.
Read Our Latest Stock Report on LENZ Therapeutics
LENZ Therapeutics Stock Performance
The firm's 50-day simple moving average is $25.91 and its 200-day simple moving average is $21.76.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.09. During the same period in the prior year, the firm earned ($1.33) earnings per share. As a group, equities research analysts anticipate that LENZ Therapeutics, Inc. will post -2.09 EPS for the current year.
Hedge Funds Weigh In On LENZ Therapeutics
Hedge funds have recently bought and sold shares of the business. American International Group Inc. bought a new stake in shares of LENZ Therapeutics during the 1st quarter valued at $44,000. SG Americas Securities LLC purchased a new position in shares of LENZ Therapeutics in the 3rd quarter worth $107,000. MetLife Investment Management LLC bought a new position in shares of LENZ Therapeutics in the 3rd quarter valued at about $182,000. GSA Capital Partners LLP bought a new stake in LENZ Therapeutics during the third quarter worth approximately $246,000. Finally, Squarepoint Ops LLC bought a new stake in shares of LENZ Therapeutics in the 2nd quarter valued at approximately $181,000. Hedge funds and other institutional investors own 54.32% of the company's stock.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Featured Stories
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
